The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Paolo A. Ascierto; Paolo Bruzzi; Alexander Eggermont; Omid Hamid; Hussein A. Tawbi; Alexander Van Akkooi; Alessandro Testori; Corrado Caracò; Igor Puzanov; Francesco Perrone

doi:10.1186/s12967-019-1892-5

The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Paolo A. Ascierto, Paolo Bruzzi, Alexander Eggermont, Omid Hamid, Hussein A. Tawbi, Alexander Van Akkooi, Alessandro Testori, Corrado Caracò, Igor Puzanov, Francesco Perrone

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

1 Citaat (Scopus)

Samenvatting

The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

Originele taal-2	Engels
Artikelnummer	148
Tijdschrift	Journal of Translational Medicine
Volume	17
Nummer van het tijdschrift	1
DOI's	https://doi.org/10.1186/s12967-019-1892-5
Status	Gepubliceerd - 10 mei 2019
Extern gepubliceerd	Ja

Toegang tot document

10.1186/s12967-019-1892-5

Citeer dit

@article{7793da4772bf4205b5bbc2ac9ad0d820,

title = "The great debate at {"}melanoma Bridge 2018{"}, Naples, December 1st, 2018",

abstract = "The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.",

keywords = "Adjuvant, Anti-CTLA-4, Anti-PD-1, BRAF inhibitor, Immunotherapy, MEK inhibitor, Melanoma, Neoadjuvant, Targeted therapy",

author = "Ascierto, {Paolo A.} and Paolo Bruzzi and Alexander Eggermont and Omid Hamid and Tawbi, {Hussein A.} and {Van Akkooi}, Alexander and Alessandro Testori and Corrado Carac{\`o} and Igor Puzanov and Francesco Perrone",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = may,

day = "10",

doi = "10.1186/s12967-019-1892-5",

language = "English",

volume = "17",

journal = "Journal of Translational Medicine",

issn = "1479-5876",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

AU - Ascierto, Paolo A.

AU - Bruzzi, Paolo

AU - Eggermont, Alexander

AU - Hamid, Omid

AU - Tawbi, Hussein A.

AU - Van Akkooi, Alexander

AU - Testori, Alessandro

AU - Caracò, Corrado

AU - Puzanov, Igor

AU - Perrone, Francesco

PY - 2019/5/10

Y1 - 2019/5/10

N2 - The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

AB - The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

KW - Adjuvant

KW - Anti-CTLA-4

KW - Anti-PD-1

KW - BRAF inhibitor

KW - Immunotherapy

KW - MEK inhibitor

KW - Melanoma

KW - Neoadjuvant

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85065589434&partnerID=8YFLogxK

U2 - 10.1186/s12967-019-1892-5

DO - 10.1186/s12967-019-1892-5

M3 - Article

C2 - 31077205

AN - SCOPUS:85065589434

SN - 1479-5876

VL - 17

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

IS - 1

M1 - 148

ER -

The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit